KalVista Pharmaceuticals Reports Fiscal First Quarter Results

KalVista Pharmaceuticals (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, provided an operational update and released financial results for the fiscal first quarter ended July 31, 2018.

As quoted in the press release:

“Our two recent financings provide significant additional capital for late stage development of KVD900, our oral plasma kallikrein inhibitor for potential treatment of on-demand acute attacks in patients with hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of KalVista. “KVD001, our intravitreal candidate for potential treatment of diabetic macular edema, or DME, currently enrolling a Phase 2 clinical trial, continues with data expected as planned in the second half of 2019. Additionally, we remain committed to our work in discovering and developing oral plasma kallikrein inhibitors for prophylactic treatment of HAE as well as DME. Finally, we recently moved to our new facility in Porton Down, England, which is intended to support our scientific team as they continue to work on discovery and development of additional drug programs.”

Click here to read the full press release.